Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease
and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that …

Cerebral Hemorrhages after t-PA in a Patient Treated with Lecanemab A patient with mild
cognitive impairment who was treated in the extension phase of a trial of lecanemab, an …

Background Findings from observational studies suggest that dietary patterns may offer
protective benefits against cognitive decline, but data from clinical trials are limited. The …